FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 755 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Making a startup out of a scientist April 26, 2023 Keanu Reeves Has A Long History Of Supporting Cancer Research January 13, 2022 EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment... May 17, 2024 For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to... August 29, 2022 Load more HOT NEWS German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... Great Oaks Grow From Small Acorns Oncology Is Committed to Doing... Teenage (…and young adult) kicks Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020
